A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Acebilustat (Primary) ; Mannitol
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Celtaxsys
  • Most Recent Events

    • 03 Nov 2016 According to a Celtaxsys media release the result from this trial published in the second paper of Clinical and Translational Science (CTS), a publication of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
    • 03 Nov 2016 Results published in the Celtaxsys Media Release.
    • 28 Oct 2016 According to a Celtaxsys media release the result from this trial will be published in the journal Clinical and Translational Science (CTS), a publication of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top